抗BCMA工程化外泌体用于硼替佐米靶向递送治疗多发性骨髓瘤
研究利用单核细胞来源外泌体经基因修饰表达抗BCMA抗体,封装硼替佐米(Btz)构建anti-BCMA-Exo-Btz递送平台。体外该平台较游离Btz抑制骨髓瘤作用更强,原位骨髓瘤异种移植模型中较游离Btz显示显著抗肿瘤效果且靶向特异性好。小鼠组织学未见明显损伤,对外周血单个核细胞影响轻微。
要点
- anti-BCMA-Exo-Btz在体外较游离Btz显示更强的骨髓瘤抑制效果
- 原位骨髓瘤异种移植模型中anti-BCMA-Exo-Btz较游离Btz显示显著抗肿瘤效果
- 小鼠经anti-BCMA-Exo-Btz治疗未见明显组织学损伤
核心结论
- 研究提示经靶向配体修饰的外泌体有望将Btz递送至骨髓瘤细胞,具有临床应用潜力。
研究设计与样本
- 研究采用单核细胞来源外泌体,经基因修饰表达靶向BCMA的抗体以封装硼替佐米,并在体外及原位骨髓瘤异种移植模型中进行评价。
主要发现
- anti-BCMA-Exo-Btz在体外较游离Btz表现出更强的骨髓瘤抑制效果。
- 原位骨髓瘤异种移植模型中anti-BCMA-Exo-Btz较游离Btz显示显著抗肿瘤效果。
- anti-BCMA-Exo-Btz在体内将Btz靶向骨髓瘤细胞显示显著特异性。
- 小鼠经anti-BCMA-Exo-Btz治疗未见明显组织学损伤,对外周血单个核细胞影响轻微。
- 单核细胞外泌体可诱导细胞凋亡、介导免疫反应并增强间充质基质细胞的成骨潜能。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Exosomes have emerged as promising vehicles for delivering therapeutic cargoes to specific cells or tissues, owing to their superior biocompatibility, reduced immunogenicity, and enhanced targeting capabilities compared with conventional drug delivery systems. In this study, we developed a delivery platform using exosomes derived from monocytes, specifically designed for targeted delivery of bortezomib (Btz) to multiple myeloma (MM) cells. Our approach involved the genetic modification of monocytes to express antibodies targeting B-cell maturation antigen (anti-BCMA), because BCMA selectively expresses on myeloma cells. This modified anti-BCMA was then efficiently incorporated into the monocyte-derived exosomes. These adapted exosomes effectively encapsulated Btz, leading to enhanced drug accessibility within MM cells and sustained intracellular accumulation over an extended period. Remarkably, our results demonstrated that anti-BCMA-modified exosome-loaded Btz (anti-BCMA-Exo-Btz) outperformed free Btz in vitro, exhibiting a more potent myeloma-suppressive effect. In orthotopic MM xenograft models, anti-BCMA-Exo-Btz exhibited a significant antitumor effect compared with free Btz. Furthermore, it demonstrated remarkable specificity in targeting Btz to myeloma cells in vivo. Importantly, we observed no significant histological damage in mice treated with anti-BCMA-Exo-Btz and a slight effect on peripheral blood mononuclear cells. In addition, our study highlighted the multifunctional potential of monocyte exosomes, which induced cell apoptosis, mediated immune responses, and enhanced the osteogenic potential of mesenchymal stromal cells. In conclusion, our study suggests that exosomes modified with targeting ligands hold therapeutic promise for delivering Btz to myelomas, offering substantial potential for clinical applications.
引用
- Yuan S, Li Q, He C, et al. Anti-BCMA-engineered exosomes for bortezomib-targeted delivery in multiple myeloma. Blood Adv. 2024. PMID: 38875465. doi:10.1182/bloodadvances.2023012464
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。